Kinetics of the immune response following pneumococcal PD conjugate vaccination. [2007.03.01]Primary vaccination with pneumococcal protein D conjugate vaccine in the first year of life induced clear ELISA and OPA responses, which varied considerably for the different serotypes. Antibody levels declined following primary vaccination but were restored (except for serotype 3) to above post-primary levels by booster vaccination in the second year of life.

Pharmacokinetics of anti-D IgG in pregnant RhD-negative women. [2003.01]OBJECTIVE: To assess the pharmacokinetics of anti-D IgG in pregnant Rhesus D-negative women after intramuscular and intravenous administration of 300 microg of Rhophylac... CONCLUSIONS: The serum concentrations of anti-D IgG measured after administration of Rhophylac were very similar to those obtained with 300 microg of a different anti-D immunoglobulin product.

The investigators want to test whether infusions of intravenous immunoglobulin - a blood

product known to modify immune responses - in early pregnancy will increase the chance of a

subsequent live birth in women with three or more miscarriages after a birth and a total of
at least four miscarriages. This will be done in a trial where 82 patients will be randomly
allocated to infusions with intravenous immunoglobulin or placebo during pregnancy.

Investigating the Role of Early Intravenous Immunoglobulin Treatment for Children With Encephalitis [Not yet recruiting]
This is a phase III multi-centre randomised, double blind, placebo controlled trial to
assess the role of intravenous immunoglobulin in the treatment of children with
encephalitis. The primary objective is to find out whether early use of IVIG treatment
improves neurological outcomes of children with encephalitis.
308 children with encephalitis, aged 6 weeks to 16 years will be recruited in 30 hospitals
in the United Kingdom. Participants will be randomised to receive two doses of IVIG or
matching placebo in addition to other standard treatments, within the first five days of
hospital admission.
Each participant will be followed up for 12 months. During this period, information on
clinical, radiological and laboratory investigations will be collected. Neurological
outcomes will be assessed by the use of questionnaires at 6 and 12 months, and a
neuropsychological assessment at 12 months.